All requests are reviewed by qualified healthcare professionals.
- Email: support@novametabolic.com
- Phone: 555
-
English
English
Metabolic Health
Mounjaro® (tirzepatide) is a prescription once-weekly injectable medication used to improve blood sugar control in adults with type 2 diabetes mellitus. It is also associated with significant weight reduction in many patients when used alongside diet and exercise. Mounjaro is a first-in-class dual GIP and GLP-1 receptor agonist, meaning it works on two incretin pathways to help regulate blood glucose levels and appetite more effectively than GLP-1 therapy alone.
Mounjaro is a first-in-class dual GIP and GLP-1 receptor agonist containing tirzepatide. It targets two incretin hormone pathways simultaneously for enhanced weight loss results.
Mounjaro activates both GIP and GLP-1 receptors, which helps:
Mounjaro is not insulin and is not approved for type 1 diabetes. It should be used under medical supervision as part of a comprehensive diabetes and lifestyle management plan.
Common side effects may include nausea, vomiting, diarrhea, constipation, reduced appetite, and abdominal discomfort, especially during dose escalation.
| Starting Dose | 2.5mg once weekly (weeks 1-4) |
|---|---|
| Dose Step 2 | 5mg once weekly (weeks 5-8) |
| Dose Step 3 | 7.5mg once weekly (weeks 9-12) |
| Dose Step 4 | 10mg once weekly (weeks 13-16) |
| Maximum Dose | 15mg once weekly |
| Administration | Subcutaneous injection — abdomen, thigh, or upper arm |
| Supply | 4-week supply per order |
| Form | Single-dose auto-injector pen |
| Active Ingredient | Tirzepatide |
| Mechanism | Dual GIP and GLP-1 receptor agonist |
| Rx Required | Yes — provider review included |
 Injection&media=https://novametabolic.com/assets/images/product/69dfa756e089a1776265046.jpg){kind=link}